Prognostic Factors for mrcc: Relevance in Clinical Practice

Size: px
Start display at page:

Download "Prognostic Factors for mrcc: Relevance in Clinical Practice"

Transcription

1

2 Prognostic Factors for mrcc: Relevance in Clinical Practice Daniel Heng MD MPH FRCPC Chair, GU Tumor Group Tom Baker Cancer Center University of Calgary

3 Prognostic Factors Patient Factors Performance Status Symptoms Tumor Burden Prior nephrectomy Sites of metastases Bone / Liver Metastases LDH Anemia Calcium Sodium Patient X Patient Y Proinflammatory Markers IL-6 ESR Neutrophilia Thrombocytosis C-reactive protein Treatment-related Patient Z Factors Prior therapy Prior radiotherapy Disease-free interval Diagnosis to treatment interval

4 MSKCC Prognostic Profiles Motzer et al JCO 2002

5 IKCWG Prognostic Criteria Manola et al Clin Cancer Res 2011

6 International mrcc Database Consortium Currently includes 3700 patients from 25 institutions

7 Int l mrcc Database Consortium Prognostic Factors KPS < 80% Dx to Tx Interval <1yr Anemia Hypercalcemia Neutrophilia Thrombocytosis Heng et al J Clin Oncol 2009

8 Prognostic Factors If patient has 0 factors: Favorable Prognosis If patient has 1-2 factors: Intermediate Prognosis If patient has 3-6 factors: Poor Prognosis

9 Prognostic Factors: Targeted Therapy Era Heng et al Lancet Oncology months 23 months 8 months

10 Benchmarks from IMDC Population (Data from IMDC) PFS (mon) (95% CI) 1 st line therapy (all pts) 7.2 ( ) n=2659 1st line therapy in intermediate/poor risk patients & diagnosis to treatment interval < 1 year (similar to ADAPT 5.6 ( ) (AGS003) pts) n=1174 OS (mon) (95%CI) 20.9 ( ) n= ( ) n=1189 1st line therapy in patients with prior nephrectomy (similar to TIVO-1 (Tivozanib) pt) 2nd line therapy (similar to INTORSECT patients) 8.2 ( ) n= ( ) n= ( ) n= ( ) n=1157 3rd line therapy (all pts) 4.0 ( ) n=425 3rd line therapy in patients with 1 prior VEGF and 1 prior mtor inhibitor (similar to GOLD (dovitinib) pts) 4.4 ( ) n= ( ) n= ( ) n=147 Ko et al BJC 2014

11 Harshman et al Lancet Oncol 2012 Conditional Survival Our prognostic criteria are used at the initiation of treatment How does survival change as you survive longer? How does survival change as you survive past the median in your risk group?

12 Harshman et al Lancet Oncol 2012 Survival of each risk group over time survived already

13 Conditional Survival in SEER Bianchi et al BJU 2013

14 The future of prognostication Reached the ceiling of clinical variables Need biologic markers to add to the accuracy of existing models IMDC model + X + Y to improve accuracy

15 Cancer Genome Atlas Research Network Nature 2013

16 Why are Prognostic Factors Important?

17 Prognostic Factors Important for patient counseling Will you live < 1 year or > 1 year? Important for clinical trial risk stratification and retrospective study adjustment methods

18 Iacovelli et al EJC 2013 Italian Database 281/2065 had 3 lines of targeted therapy VEGF VEGF mtor vs VEGF mtor VEGF HR 2.59 ( ) after adjusting for prognostic criteria Assumes patients make it to three lines of therapy No axitinib in study

19 Prognostic Factors Important for planning therapy We use temsirolimus for poor risk patients Is active surveillance appropriate for small bulk, not growing, favorable risk, highly selected patients Is cytoreductive nephrectomy appropriate?

20 Cytoreductive Nephrectomy 3245 mrcc patients 676/1658 (41%) No nephrectomy 2569 (79%) patients with nephrectomy 982/1658 (59%) Cytoreductive Nephrectomy EXCLUDED 1587 (49%) w/ nephrectomy prior to metastases FINAL NUMBERS

21 Overall Survival Overall Survival Median OS 20.6 vs 9.5 months (p<0.0001) Adjusted HR 0.60 (95%CI , p<0.0001) Cytoreductive nephrectomy No Cytoreductive nephrectomy Months Since Initiation of Targeted Therapy

22 HR adjusted for IMDC criteria: 0.60 (95%CI , p<0.0001)

23 Incremental Benefit Overall Survival (Months) No CN OS (Months) < n=456 < n=430 < n=366 <9 4.5 n=303 <6 3.2 n=230 <3 2.1 n=118 CN OS (Months) 12.3 n= n= n= n= n= n=71 P-value < < <

24 Incremental Benefit Overall Survival (Months) No CN OS (Months) < n=456 < n=430 < n=366 <9 4.5 n=303 <6 3.2 n=230 <3 2.1 n=118 CN OS (Months) 12.3 n= n= n= n= n= n=71 P-value Incremental Benefit (Months) < < <

25 Incremental Benefit Overall Survival (Months) No CN OS (Months) < n=456 < n=430 < n=366 <9 4.5 n=303 <6 3.2 n=230 <3 2.1 n=118 CN OS (Months) 12.3 n= n= n= n= n= n=71 P-value Incremental Benefit (Months) Hazard Ratio Adjusted for IMDC Criteria < ( ) p< < ( ) p= < ( ) p= ( ) p= ( ) p= ( ) p=0.8782

26 Using IMDC Prognostic Factors # of IMDC Criteria Met No CN OS months (N) CN OS months (N) P value 0 92% (65/71) patients had CN, insufficient number to compare (n=72) 30.4 (n=178) (n=143) 20.2 (n=253) < (n=113) 15.9 (n=106) < (n=103) 6.0 (n=67) (n=36) 2.8 (n=14) % (3/12) patients had CN, insufficient number to compare

27 Cytoreductive Nephrectomy Perhaps not appropriate in patients with survival estimated to be < 1 year Perhaps not appropriate in patients with 4 or more adverse prognostic factors

28 Prognosis Is important for patient counseling, study design, and planning therapy Prognosis is dynamic Prognosis needs to be improved with biomarkers THANK YOU!

29

Metastatic renal cancer (mrcc): Evidence-based treatment

Metastatic renal cancer (mrcc): Evidence-based treatment Metastatic renal cancer (mrcc): Evidence-based treatment José M. Ruiz Morales, M.D. Hospital Médica Sur April 18th, 2018 4th ESO-ESMO Latin American Masterclass in Clinical Oncology Disclosures Consulting:

More information

Characterization of Patients with Poor-

Characterization of Patients with Poor- Characterization of Patients with Poor- Risk Metastatic Renal Cell Carcinoma Hamieh L 1 *, McKay RR 1 *, Lin X 2, Simantov R 2, Choueiri TK 1 *Equal contributions 1 Dana-Farber Cancer Institute, Boston,

More information

Cytoreductive Nephrectomy

Cytoreductive Nephrectomy Cytoreductive Nephrectomy Stephen H. Culp, M.D., Ph.D. Assistant Professor, Department of Urology Outline The Historics of CN The current status of CN The importance of patient selection Cytoreductive

More information

CLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY FOR THE RIGHT PATIENT

CLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY FOR THE RIGHT PATIENT Daniel Heng, MD, MPH, FRCPC @DrDanielHeng Chair GU Tumour Group, Tom Baker Cancer Centre Clinical Professor, University of Calgary CLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY

More information

Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense?

Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense? Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense? Philippe E. Spiess, MD, FACS Associate Member Department of GU Oncology Department of Tumor Biology Moffitt Cancer

More information

Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better?

Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial

More information

David N. Robinson, MD

David N. Robinson, MD David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell

More information

Winship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients

Winship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients Winship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients Bradley Carthon, MD, PhD Assistant Professor, Genitourinary Medical Oncology Winship

More information

Medical Management of Renal Cell Carcinoma

Medical Management of Renal Cell Carcinoma Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,

More information

Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?

Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?

More information

Timing of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital

Timing of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 1 Timing of targeted therapy in patients with low volume mrcc Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 2 Wont be discussing: Symptomatic patients High volume disease Rapidly growing metastases

More information

Management of High Risk Renal Cell Carcinoma

Management of High Risk Renal Cell Carcinoma Management of High Risk Renal Cell Carcinoma Peter E. Clark, MD Professor and Chair, Department of Urology Carolinas HealthCare System Chair, Urologic Oncology Levine Cancer Institute October 14, 2017

More information

Linee guida terapeutiche oncologiche. Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona

Linee guida terapeutiche oncologiche. Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona Linee guida terapeutiche oncologiche Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona 1 YOUNG SPECIALIST RENAL CARE Verona, 07-08 Marzo 2014 Clinical

More information

UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA

UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA DISCLAIMER Please note: The views expressed within this presentation

More information

Sequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC

Sequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Sequencing of therapies in mrcc Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Old Paradigm Sequencing approved agents VEGF TKI Sunitinib Pazopanib Axitinib TKI TKI MTORi

More information

The Therapeutic Landscape in Advanced Renal Cell Carcinoma

The Therapeutic Landscape in Advanced Renal Cell Carcinoma The Therapeutic Landscape in Advanced Renal Cell Carcinoma Cora Sternberg, MD, FACP Chairman, Department of Medical Oncology San Camillo-Forlanini Hospital Rome, Italy What best describes the change in

More information

I Kid(ney) You Not: Updates on Renal Cell Carcinoma

I Kid(ney) You Not: Updates on Renal Cell Carcinoma Disclosures I Kid(ney) You Not: Updates on Renal Cell Carcinoma Nothing to disclose Renee McAlister, PharmD, BCOP Clinical Pharmacist, GU/Melanoma Vanderbilt Ingram Cancer Center September 29, 2018 Objectives

More information

Sergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy

Sergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26

More information

Why was HOPE 205 a Positive After Years of Negative Studies?

Why was HOPE 205 a Positive After Years of Negative Studies? Why was HOPE 205 a Positive After Years of Negative Studies? Prof. Dr. med. Viktor Grünwald Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation Why do we pursue combinations?

More information

Kidney Cancer Session

Kidney Cancer Session New Frontiers in Urologic Oncology September 12 th, 2015 Kidney Cancer Session Moderator: Philippe E. Spiess, M.D. Invited Faculty Members: Wade J. Sexton, MD Jeremiah J. Morrissey, PhD Agenda for Session

More information

Multidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute

Multidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute Multidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 20 April, Antalya, Turkey RCC European Union 60.000 new diagnoses/year 26.000 Cancer related deaths

More information

Renal Cell Carcinoma: Status of Medical and Surgical Therapy. Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation

Renal Cell Carcinoma: Status of Medical and Surgical Therapy. Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation Renal Cell Carcinoma: Status of Medical and Surgical Therapy Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation Metastatic Renal Cell Carcinoma: Evolution of Current Therapeutic Approaches

More information

Lymphadenectomy in RCC: Yes, No, Clinical Trial?

Lymphadenectomy in RCC: Yes, No, Clinical Trial? Lymphadenectomy in RCC: Yes, No, Clinical Trial? Viraj Master MD PhD FACS Professor Associate Chair for Clinical Affairs and Quality Director of Clinical Research Unit Department of Urology Emory University

More information

Evidenze cliniche nel trattamento del RCC

Evidenze cliniche nel trattamento del RCC Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,

More information

New strategies and future of target therapy in advanced kidney cancer

New strategies and future of target therapy in advanced kidney cancer New strategies and future of target therapy in advanced kidney cancer VHL Gene Inactivation VHL Complex Disrupted VHL Protein HIF1-a, HIF2-a Accumulation VEGF PDGF TGF-α, CXCR4 Angiogenesis Endothelial

More information

Second - Line Debate: Axitinib

Second - Line Debate: Axitinib Second - Line Debate: Axitinib Alain Ravaud, MD PhD Bordeaux, France DISCLOSURES Member of Global, European and/or French advisory board in RCC and/or GU tumors for Pfizer, Novartis, GSK, Roche, BMS, Merck.

More information

Emerging Biomarkers of VEGF and mtor Inhibitors in 2015

Emerging Biomarkers of VEGF and mtor Inhibitors in 2015 Emerging Biomarkers of VEGF and mtor Inhibitors in 2015 Laurence Albiges Institut Gustave Roussy, France Fourteenth International Kidney Cancer Symposium Miami, Florida, USA November 6-7, 2015 www.kidneycancersymposium.com

More information

Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?

Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE

More information

Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy

Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures

More information

Integrating novel therapy in advanced renal cell carcinoma

Integrating novel therapy in advanced renal cell carcinoma Integrating novel therapy in advanced renal cell carcinoma Tian Zhang, MD Assistant Professor of Medicine GU Oncology Duke Cancer Institute March 11, 2017 Disclosures Research Funding Janssen Pfizer Consultant

More information

Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea

Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre I + 12

More information

Advances in the Treatment of Renal Cell Carcinoma

Advances in the Treatment of Renal Cell Carcinoma Advances in the Treatment of Renal Cell Carcinoma Developed in collaboration Learning Objectives Upon completion, participants should be able to: Identify patients with metastatic renal cell carcinoma

More information

Plasma fibrinogen as prognostic predictor in patients with metastatic renal cell carcinoma receiving target therapy

Plasma fibrinogen as prognostic predictor in patients with metastatic renal cell carcinoma receiving target therapy Original Article Plasma fibrinogen as prognostic predictor in patients with metastatic renal cell carcinoma receiving target therapy Lihe Wang 1#, Wen Cai 2#, Wen Kong 2, Jin Zhang 2, Yonghui Chen 2, Jiwei

More information

The role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy

The role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy The role of cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in an era of targeted therapy Dipesh Uprety, MD Amir Bista, MD Yazhini Vallatharasu, MD Angela Smith, MA David

More information

Complete Remission is a Reachable Goal in mrcc L. Albiges Institut Gustave Roussy

Complete Remission is a Reachable Goal in mrcc L. Albiges Institut Gustave Roussy Complete Remission is a Reachable Goal in mrcc L. Albiges Institut Gustave Roussy Is complete remission an achievable goal in mrcc? Lessons from observation Lessons from immunotherapy Current status in

More information

Carcinoma renale (I): Posters Review. Elena Verzoni Oncologia Medica 1 SS.Oncologia Genitourinaria Fondazione IRCCS Istituto Nazionale Tumori Milano

Carcinoma renale (I): Posters Review. Elena Verzoni Oncologia Medica 1 SS.Oncologia Genitourinaria Fondazione IRCCS Istituto Nazionale Tumori Milano Carcinoma renale (I): Posters Review Elena Verzoni Oncologia Medica 1 SS.Oncologia Genitourinaria Fondazione IRCCS Istituto Nazionale Tumori Milano Agenda: Best Posters in Localized RCC Surgery: CN (#

More information

Renal Cell Carcinoma

Renal Cell Carcinoma Renal Cell Carcinoma Sequencing in renal cancer: two options for the same problem (TKImTOR) Viktor Grünwald Clinic for Hematology, Hemostasis, Oncology and Stemcelltransplantation Prof. Viktor Grünwald

More information

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT ipilimumab aligned with patient values. Although few patients had direct experience using this combination agent, patients indicated that side effects associated with nivolumab plus ipilimumab were few

More information

Prognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will Be Used?

Prognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will Be Used? european urology supplements 8 (2009) 478 482 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will

More information

Treatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents

Treatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents Conflict of Interest Treatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents None Patrick Medina, PharmD, BCOP Associate Professor University of Oklahoma OKC, OK Learning Objectives Epidemiology

More information

A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care

A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care Martin H. Voss 1, Thomas Hutson 2, Arif Hussain 3, Ulka

More information

NEXT GENERATION DRUGS IN KIDNEY CANCER. Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden

NEXT GENERATION DRUGS IN KIDNEY CANCER. Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden NEXT GENERATION DRUGS IN KIDNEY CANCER Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden KIDNEY CANCER SUBTYPES Papillary Type 1 and 2 Medullary Collecting duct Chromophobe Translocation Clear cell

More information

Innovaciones en el tratamiento del ca ncer renal. Enrique Grande

Innovaciones en el tratamiento del ca ncer renal. Enrique Grande Innovaciones en el tratamiento del ca ncer renal Enrique Grande The enriched inflammatory environment of RCC Chen Z, et al. Nat Rev Cancer 2014 Available agents are expanding across the three eras of arcc

More information

Treatment Algorithm and Therapy Management in mrcc. Manuela Schmidinger Medical University of Vienna Austria

Treatment Algorithm and Therapy Management in mrcc. Manuela Schmidinger Medical University of Vienna Austria Treatment Algorithm and Therapy Management in mrcc Manuela Schmidinger Medical University of Vienna Austria A Paradigm Shift in the Treatment of mrcc 1. Sunitinib 2. Sorafenib 3. Bevacizumab+IFN-alpha

More information

Toxicity as a Biomarker

Toxicity as a Biomarker Toxicity as a Biomarker Frede Donskov, M.D., PhD Chair, Danish Renal Cancer Group, DARENCA Aarhus University Hospital Denmark Thirteenth International COI Research funding from Novartis, GSK, Pfizer and

More information

Developping the next generation of studies in RCC

Developping the next generation of studies in RCC Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,

More information

Case(s): How to Deal with Mixed Response Giuseppe Procopio

Case(s): How to Deal with Mixed Response Giuseppe Procopio Case(s): How to Deal with Mixed Response Giuseppe Procopio Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Disclosures Advisory: Astellas, Bayer, GSK Consultant: Pfizer, Novartis Background Mixed

More information

Fifteenth International Kidney Cancer Symposium

Fifteenth International Kidney Cancer Symposium The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee

More information

Dose individualization of sunitinib in mrcc: Toxicity-adjusted dose or Therapeutic drug monitoring

Dose individualization of sunitinib in mrcc: Toxicity-adjusted dose or Therapeutic drug monitoring Dose individualization of sunitinib in mrcc: Toxicity-adjusted dose or Therapeutic drug monitoring Alison Zhang 1, Peter Fox 1, Sally Coulter 4, Val Gebski 5, Bavanthi Balakrishnar 1, Christopher Liddle

More information

CON: Removal of the Breast Primary in Patients with Metastatic Breast Cancer

CON: Removal of the Breast Primary in Patients with Metastatic Breast Cancer CON: Removal of the Breast Primary in Patients with Metastatic Breast Cancer Amelia B. Zelnak, M.D., M.Sc. Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute Emory University

More information

Targeted Therapy in Advanced Renal Cell Carcinoma

Targeted Therapy in Advanced Renal Cell Carcinoma Targeted Therapy in Advanced Renal Cell Carcinoma Brian I. Rini, M.D. Department of Solid Tumor Oncology Glickman Urologic and Kidney Institute Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio

More information

Introduction. pissn , eissn Cancer Res Treat. 2014;46(4):

Introduction. pissn , eissn Cancer Res Treat. 2014;46(4): pissn 1598-2998, eissn 2005-9256 Original Article http://dx.doi.org/10.4143/crt.2013.154 Open Access Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following

More information

Renal Cell Carcinoma: Systemic Therapy Progress and Promise

Renal Cell Carcinoma: Systemic Therapy Progress and Promise Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.

More information

Metastatic Renal Cancer Medical Treatment

Metastatic Renal Cancer Medical Treatment Metastatic Renal Cancer Medical Treatment Bohuslav Melichar, M.D., Ph.D. Professor and Head Department of Oncology Palacký University Medical School and Teaching Hospital Olomouc, Czech Republic Peculiarities

More information

Revisione Oral Abstracts

Revisione Oral Abstracts Revisione Oral Abstracts Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi UPDATES and NEWS from the Genitourinary Cancers Symposium - Milano,

More information

The High-Dose Aldesleukin (IL-2) Select Trial in Patients with Metastatic RCC

The High-Dose Aldesleukin (IL-2) Select Trial in Patients with Metastatic RCC The High-Dose Aldesleukin (IL-2) Select Trial in Patients with Metastatic RCC D McDermott, M Ghebremichael, S Signoretti, K Margolin, J Clark, J Sosman, J Dutcher, T Logan, R Figlin and M Atkins on behalf

More information

CANCER UROLOGY VOL. 12. P. S. Borisov 1, M. I. Shkol nik 2, R. V. Orlova 3, P. A. Karlov 1 DOI: /

CANCER UROLOGY VOL. 12. P. S. Borisov 1, M. I. Shkol nik 2, R. V. Orlova 3, P. A. Karlov 1 DOI: / CANCER UROLOGY 3 6 VOL. The use of targeted therapies and selection of the optimal treatment sequence in heterogeneous population of patients with metastatic kidney cancer. Results of retrospective study

More information

Brain mets under I.O.

Brain mets under I.O. Brain mets under I.O. Bernard Escudier Gustave Roussy, Villejuif, France Disclosure Honorarium received from BMS, Novartis, Pfizer, Bayer, Roche, Exelixis, Ipsen, Eisai, Calithera Travel Grant from BMS,

More information

Cytoreductive nephrectomy and its role in the present-day period of targeted therapy

Cytoreductive nephrectomy and its role in the present-day period of targeted therapy 585501TAU0010.1177/1756287215585501Therapeutic Advances in UrologySH Culp review-article2015 Therapeutic Advances in Urology Review Cytoreductive nephrectomy and its role in the present-day period of targeted

More information

Medical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce

Medical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce Medical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce Medical treatment of metastatic RCC in the elderly ( 65y): Members of the SIOG Taskforce

More information

Brain metastases and meningitis carcinomatosa: Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland

Brain metastases and meningitis carcinomatosa: Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland Brain metastases and meningitis carcinomatosa: a palliative situation? Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland SAMO, Lucerne, February 1-2, 2013 Treatment options for NSCLC patients

More information

Surgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute

Surgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute Surgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 23 March 2012, Sao Paulo, Brazil Surgery of RCC Locally confined (small) renal tumours Locally advanced disease Metastatic

More information

DISCLOSURE SLIDE. ARGOS: research funding, scientific advisory board

DISCLOSURE SLIDE. ARGOS: research funding, scientific advisory board INTERIM ANALYSIS OF THE PHASE 3 ADAPT TRIAL EVALUATING ROCAPULDENCEL-T (AGS-003), AN INDIVIDUALIZED IMMUNOTHERAPY FOR THE TREATMENT OF NEWLY-DIAGNOSED PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)

More information

E2804 The BeST Trial

E2804 The BeST Trial E2804 The BeST Trial A randomized Phase II Study of VEGF, RAF Kinase and MTOR Combination Targeted Therapy with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma Investigators Keith

More information

Renal Cell Carcinoma: Navigating a Maze of Choices

Renal Cell Carcinoma: Navigating a Maze of Choices Renal Cell Carcinoma: Navigating a Maze of Choices Sumanta Kumar Pal, M.D. Associate Professor Department of Medical Oncology & Experimental Therapeutics Co-Director, Kidney Cancer Program City of Hope

More information

Renal Cell Cancer: Present and Future. Bernard Escudier, Gustave Roussy

Renal Cell Cancer: Present and Future. Bernard Escudier, Gustave Roussy Renal Cell Cancer: Present and Future Bernard Escudier, Gustave Roussy [HKIOF May 2017] Sponsored by Bristol- Myers Squibb OPDIVO Hong Kong prescribing information is available upon request Disclosures

More information

Research Report. ISSN /17/$ IOS Press and the authors. All rights reserved

Research Report. ISSN /17/$ IOS Press and the authors. All rights reserved Kidney Cancer 1 (2017) 41 47 DOI 10.3233/KCA-160002 IOS Press Research Report 41 Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrrcc) in the Targeted Therapy Era: Results from the International

More information

ACRIN Gynecologic Committee

ACRIN Gynecologic Committee ACRIN Gynecologic Committee Fall Meeting 2010 ACRIN Abdominal Committee Biomarkers & Endpoints in Ovarian Cancer Trials Robert L. Coleman, MD Professor and Vice Chair, Clinical Research Department of Gynecologic

More information

OVERVIEW OF GENE EXPRESSION-BASED TESTS IN EARLY BREAST CANCER

OVERVIEW OF GENE EXPRESSION-BASED TESTS IN EARLY BREAST CANCER OVERVIEW OF GENE EXPRESSION-BASED TESTS IN EARLY BREAST CANCER Aleix Prat, MD PhD Medical Oncology Department Hospital Clínic of Barcelona University of Barcelona esmo.org Disclosures Advisory role for

More information

INTEGRATION OF SURGERY AND SYSTEMIC THERAPY FOR ADVANCED RENAL CELL CARCINOMA IN THE TARGETED THERAPY ERA

INTEGRATION OF SURGERY AND SYSTEMIC THERAPY FOR ADVANCED RENAL CELL CARCINOMA IN THE TARGETED THERAPY ERA INTEGRATION OF SURGERY AND SYSTEMIC THERAPY FOR ADVANCED RENAL CELL CARCINOMA IN THE TARGETED THERAPY ERA Dr. Michael J. Metcalfe PGY-4 Department of Urologic Sciences University of British Columbia October

More information

Clinical Biomarker in Kidney Cancer. Maria Nirvana Formiga, M.D., Ph.D.

Clinical Biomarker in Kidney Cancer. Maria Nirvana Formiga, M.D., Ph.D. Clinical Biomarker in Kidney Cancer Maria Nirvana Formiga, M.D., Ph.D. Disclosures I am on the Speaker s Bureau with Pfizer and Bayer Clinical trials of BMS and Pfizer Kidney Cancer 70% new cases in developed

More information

Reference No: Author(s) Approval date: June Committee. Operational Date: July Review:

Reference No: Author(s) Approval date: June Committee. Operational Date: July Review: Reference No: Title: Author(s) Systemic anti-cancer therapy (SACT) guidelines for renal cell cancer Dr Alison Clayton Consultant Medical Oncologist & Dr Jane Hurwitz Consultant Medical Oncologist, Cancer

More information

Current experience in immunotherapy for metastatic renal cell carcinoma

Current experience in immunotherapy for metastatic renal cell carcinoma Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,

More information

Fifteenth International Kidney Cancer Symposium

Fifteenth International Kidney Cancer Symposium The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee

More information

WHAT IS THE ROLE OF ACTIVE SURVEILLANCE

WHAT IS THE ROLE OF ACTIVE SURVEILLANCE WHAT IS THE ROLE OF ACTIVE SURVEILLANCE IN THE CONTEXT OF RENAL ABLATION AND PARTIAL NEPHRECTOMY? Alessandro Volpe University of Eastern Piedmont Novara, Italy RCC INCIDENCE SEER DATABASE (1975-2006) RCC

More information

Integration of Surgery And Systemic Therapy In The Treatment of

Integration of Surgery And Systemic Therapy In The Treatment of Integration of Surgery And Systemic Therapy In The Treatment of Advanced Renal Cell Carcinoma Christopher G. Wood, M. D., FACS Professor and Deputy Chairman Douglas E. Johnson, M. D. Professorship In Urology

More information

Renal Cell Carcinoma Updated February 2016 by Dr. Safiya Karim (PGY 5 Medical Oncology Resident, University of Toronto)

Renal Cell Carcinoma Updated February 2016 by Dr. Safiya Karim (PGY 5 Medical Oncology Resident, University of Toronto) Renal Cell Carcinoma Updated February 2016 by Dr. Safiya Karim (PGY 5 Medical Oncology Resident, University of Toronto) Reviewed by Dr. Nimira Alimohamed (Staff Medical Oncologist, University of Calgary)

More information

The Use of Inhibitors of Angiogenesis in Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer: Guideline Recommendations

The Use of Inhibitors of Angiogenesis in Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer: Guideline Recommendations Evidence-Based Series #3-8-4: Section 1 The Use of Inhibitors of Angiogenesis in Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer: Guideline Recommendations S. Hotte, T. Waldron,

More information

PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH CHEMOTHERAPY

PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH CHEMOTHERAPY Journal of IMAB ISSN: 1312-773X http://www.journal-imab-bg.org http://dx.doi.org/10.5272/jimab.2016221.1045 Journal of IMAB - Annual Proceeding (Scientific Papers) 2016, vol. 22, issue 1 PROGNOSTIC FACTORS

More information

La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD

La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University

More information

Aalborg Universitet. Published in: Acta Oncologica. DOI (link to publication from Publisher): / X

Aalborg Universitet. Published in: Acta Oncologica. DOI (link to publication from Publisher): / X Aalborg Universitet A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma Soerensen, Anne V; Geertsen, Poul F; Christensen, Ib

More information

Local survival outcomes in metastatic renal cell carcinoma

Local survival outcomes in metastatic renal cell carcinoma Local survival outcomes in metastatic renal cell carcinoma Gerald Busuttil, Joseph Attard, David Farrugia, John Sciberras, Stephen Mattocks, Karl German, Patrick Zammit Abstract A quarter of patients who

More information

What can we expect from running phase III trials: will all of them alter the current treatment algorithm?

What can we expect from running phase III trials: will all of them alter the current treatment algorithm? What can we expect from running phase III trials: will all of them alter the current treatment algorithm? 8 th European International Kidney Cancer Symposium Budapest, May 2013 Martin Gore PhD FRCP Royal

More information

Role of SBRT in the management of lung and liver metastases. Ronan TANGUY, M.D. Radiation Oncologist

Role of SBRT in the management of lung and liver metastases. Ronan TANGUY, M.D. Radiation Oncologist Role of SBRT in the management of lung and liver metastases Ronan TANGUY, M.D. Radiation Oncologist Oligometastatic RCC mrcc: Lung, Bone, Liver, Brain (Schlesinger-Raab, EJC2008) Targeted therapies Objective

More information

A Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients

A Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients A Phase II Study of With or Without Bevacizumab vs in Untreated Metastatic Renal Cell Carcinoma Patients David McDermott, 1 Michael Atkins, 2 Robert Motzer, 3 Brian Rini, 4 Bernard Escudier, 5 Lawrence

More information

Positioning Antiangiogenesis Drugs and Other Agents in Renal Cell Cancer Treatment

Positioning Antiangiogenesis Drugs and Other Agents in Renal Cell Cancer Treatment Positioning Antiangiogenesis Drugs and Other Agents in Renal Cell Cancer Treatment Ahmad Awada, MD, PhD Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles (U.L.B.) Brussels, Belgium

More information

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT into consideration the concerns of the patient. Upon reconsideration of the perc Initial Recommendation,the Committee discussed feedback from the patient advocacy group reporting concerns that the definition

More information

Speaker s Bureau. Travel expenses. Advisory Boards. Stock. Genentech Invuity Medtronic Pacira. Faxitron. Dune TransMed7 Genomic Health.

Speaker s Bureau. Travel expenses. Advisory Boards. Stock. Genentech Invuity Medtronic Pacira. Faxitron. Dune TransMed7 Genomic Health. Management of DCIS Shawna C. Willey, MD, FACS Professor of Surgery, Georgetown University Director, Medstar Regional Breast Health Program Chief, Department of Surgery Medstar Georgetown University Hospital

More information

How does histology alter treatment? Cora N. Sternberg, MD, FACP Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy

How does histology alter treatment? Cora N. Sternberg, MD, FACP Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy How does histology alter treatment? Cora N. Sternberg, MD, FACP Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Targeting VHL/HIF in Clear Cell RCC VHL Bevacizumab (Antibody)

More information

Optimal Management of Isolated HER2+ve Brain Metastases

Optimal Management of Isolated HER2+ve Brain Metastases Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013 Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not

More information

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year

More information

Disclosure for Dr. Gomez

Disclosure for Dr. Gomez Local Consolidative Therapy (LCT) Improves Overall Survival (OS) Compared to Maintenance Therapy/Observation in Oligometastatic Non-Small Cell Lung Cancer (NSCLC): Final Results of a Multicenter, Randomized,

More information

Who are Candidates for Laparoscopic or Open Radical Nephrectomy. Arieh Shalhav

Who are Candidates for Laparoscopic or Open Radical Nephrectomy. Arieh Shalhav Who are Candidates for Laparoscopic or Open Radical Nephrectomy Arieh Shalhav Fritz Duda Chair of Urologic Surgery Professor of Surgery and the Comprehensive Cancer Research Center Who are Candidates for

More information

Presentation with lymphadenopathy

Presentation with lymphadenopathy Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited

More information

Surgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database

Surgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database Surgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database Hadi Khan, MD 1, Adam J. Olszewski, MD 2 and Ponnandai S. Somasundar, MD 1 1 Department

More information

Poor-prognostic advanced Germ Cell Tumors

Poor-prognostic advanced Germ Cell Tumors 14-10-16 Poor-prognostic advanced Germ Cell Tumors Karim Fizazi, MD, PhD Institut Gustave Roussy, France Metastatic GCT: Prognosis (IGCCC) Good prognosis Intermediate prognosis Poor prognosis J Clin Oncol

More information

Efficacy and Toxicity of Sunitinib in Metastatic Renal Cell Carcinoma Patients in Egypt

Efficacy and Toxicity of Sunitinib in Metastatic Renal Cell Carcinoma Patients in Egypt DOI:http://dx.doi.org/10.7314/APJCP.2015.16.5.1971 Efficacy and Toxicity of Sunitinib in Egyptian Patients with Metastatic Renal Cell Carcinoma RESEARCH ARTICLE Efficacy and Toxicity of Sunitinib in Metastatic

More information

The Really Important Questions Current Immunotherapy Trials are Not Answering

The Really Important Questions Current Immunotherapy Trials are Not Answering The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway

More information

How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES

How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I Choose First Line Treatment in Follicular Lymphoma in 2017? 1. How do I take into account

More information

When to Treat Beyond Progression with Systemic Therapies? Manuela Schmidinger Medical University of Vienna, Austria

When to Treat Beyond Progression with Systemic Therapies? Manuela Schmidinger Medical University of Vienna, Austria When to Treat Beyond Progression with Systemic Therapies? Manuela Schmidinger Medical University of Vienna, Austria Is Treatment Beyond Progression a Valid Strategy? 1) NO YES? Is Treatment Beyond Progression

More information